Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
VCN-01 by Theriva Biologics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
VCN-01 is under clinical development by Theriva Biologics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
VCN-01 by Theriva Biologics for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
VCN-01 is under clinical development by Theriva Biologics and currently in Phase I for Recurrent Head And Neck Squamous Cell...
VCN-01 by Theriva Biologics for Epithelial Ovarian Cancer: Likelihood of Approval
VCN-01 is under clinical development by Theriva Biologics and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData,...
VCN-01 by Theriva Biologics for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
VCN-01 is under clinical development by Theriva Biologics and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According...
VCN-01 by Theriva Biologics for High-Grade Glioma: Likelihood of Approval
VCN-01 is under clinical development by Theriva Biologics and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase...